Assembly Biosciences, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Assembly Biosciences, Inc. (ASMB) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-19
- Assembly Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $2.44M.
- Assembly Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00.
- Assembly Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- Assembly Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- Assembly Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Assembly Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $1.97M, a 19.49% decline from fiscal 2023.
- Assembly Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $2.44M, a 1328.07% increase from fiscal 2022.
- Assembly Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $171.00K, a 35.71% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-19 | |||||||
| 2024-12-31 | $1.97M 10-K · filed 2026-03-19 | |||||||
| 2023-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $2.44M derived: sum of 2 quarters · filed 2025-03-20 | $2.44M 10-K · filed 2025-03-20 | |||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | ||||||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 | |||||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $171.00K derived: sum of 3 quarters · filed 2024-03-28 | $171.00K 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $171.00K derived: sum of 2 quarters · filed 2023-11-08 | $171.00K 10-Q · filed 2023-11-08 | $171.00K derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $171.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $171.00K 10-Q · filed 2023-08-09 | $171.00K derived: sum of 3 quarters · filed 2023-08-09 | $171.00K derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | $0.00 derived: sum of 2 quarters · filed 2023-03-22 | $0.00 derived: sum of 3 quarters · filed 2023-03-22 | $84.00K derived: sum of 4 quarters · filed 2023-03-22 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $0.00 derived: sum of 2 quarters · filed 2023-03-22 | $84.00K derived: sum of 3 quarters · filed 2023-03-22 | $126.00K 10-K · filed 2023-03-22 | ||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $84.00K derived: sum of 2 quarters · filed 2022-11-08 | $126.00K 10-Q · filed 2022-11-08 | $365.00K derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $126.00K 10-Q · filed 2022-08-09 | $365.00K derived: sum of 3 quarters · filed 2022-08-09 | $883.00K derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $42.00K 10-Q · filed 2022-05-12 | $281.00K derived: sum of 2 quarters · filed 2022-05-12 | $799.00K derived: sum of 3 quarters · filed 2022-05-12 | $982.00K derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $239.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $757.00K derived: sum of 2 quarters · filed 2022-03-11 | $940.00K derived: sum of 3 quarters · filed 2022-03-11 | $1.30M 10-K · filed 2022-03-11 | ||||
| 2020-09-30 | $518.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $701.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.06M 10-Q · filed 2021-11-04 | $1.06M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | $183.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $545.00K 10-Q · filed 2021-08-05 | $545.00K derived: sum of 3 quarters · filed 2021-08-05 | $1.47M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | $362.00K 10-Q · filed 2021-05-06 | $362.00K derived: sum of 2 quarters · filed 2021-05-06 | $1.29M derived: sum of 3 quarters · filed 2021-05-06 | $1.69M derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $928.00K derived: sum of 2 quarters · filed 2021-02-25 | $1.33M derived: sum of 3 quarters · filed 2021-02-25 | $15.26M 10-K · filed 2021-02-25 | $1.33M 10-K · filed 2020-03-04 | |||
| 2019-09-30 | $928.00K 10-Q · filed 2019-11-07 | $1.33M derived: sum of 2 quarters · filed 2019-11-07 | $15.26M 10-Q · filed 2020-11-05 | $1.33M 10-Q · filed 2019-11-07 | ||||
| 2019-06-30 | $400.00K 10-Q · filed 2019-08-05 | $14.22M 10-Q · filed 2020-08-05 | $400.00K 10-Q · filed 2019-08-05 | |||||
| 2019-03-31 | $13.93M 10-Q · filed 2020-05-08 | $0.00 10-Q · filed 2019-05-09 | ||||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |